Login
Registrieren
Passwort zurücksetzen
Veröffentlichen & Verteilen
Verlagslösungen
Vertriebslösungen
Themen
Allgemein
Altertumswissenschaften
Architektur und Design
Bibliotheks- und Informationswissenschaft, Buchwissenschaft
Biologie
Chemie
Geowissenschaften
Geschichte
Industrielle Chemie
Informatik
Jüdische Studien
Kulturwissenschaften
Kunst
Linguistik und Semiotik
Literaturwissenschaft
Materialwissenschaft
Mathematik
Medizin
Musik
Pharmazie
Philosophie
Physik
Rechtswissenschaften
Sozialwissenschaften
Sport und Freizeit
Technik
Theologie und Religion
Wirtschaftswissenschaften
Veröffentlichungen
Zeitschriften
Bücher
Konferenzberichte
Verlage
Blog
Kontakt
Suche
EUR
USD
GBP
Deutsch
English
Deutsch
Polski
Español
Français
Italiano
Warenkorb
Home
Zeitschriften
Asian Biomedicine
Band 16 (2022): Heft 2 (April 2022)
Uneingeschränkter Zugang
Atorvastatin reduces alloxan-induced impairment of aversive stimulus memory in mice
Osman Kukula
Osman Kukula
und
Caner Günaydın
Caner Günaydın
| 29. Apr. 2022
Asian Biomedicine
Band 16 (2022): Heft 2 (April 2022)
Über diesen Artikel
Vorheriger Artikel
Nächster Artikel
Zusammenfassung
Artikel
Figuren und Tabellen
Referenzen
Autoren
Artikel in dieser Ausgabe
Vorschau
PDF
Zitieren
Teilen
Article Category:
Original article
Online veröffentlicht:
29. Apr. 2022
Seitenbereich:
71 - 78
DOI:
https://doi.org/10.2478/abm-2022-0009
Schlüsselwörter
alloxan
,
atorvastatin
,
avoidance learning
,
diabetes mellitus
,
experimental
,
memory
© 2022 Osman Kukula et al., published by Sciendo
This work is licensed under the Creative Commons Attribution 4.0 International License.
Figure 1
(A) Mouse weight throughout the experiment analyzed with a general linearized model. #P < 0.05, ###P < 0.001 alloxan-induced diabetes vs. vehicle control. ***P < 0.001 liraglutide + alloxan-induced diabetes vs. alloxan-induced diabetes. (B) Blood glucose levels after oral glucose administration for each experimental group in the OGTT. (C) Locomotor activity for each experimental group. Statistical analyses were conducted using a one-way ANOVA with a Tukey post hoc test. Data are represented as mean ± standard deviation. ANOVA, analysis of variance; Ator, atorvastatin; Control, saline vehicle treatment alone as a negative control; DM, alloxan-induced model of diabetes mellitus; OGTT, oral glucose tolerance test.
Figure 2
Effect of each drug treatment on (A) initial latency and (B) retention period latency in the passive avoidance test. There were no significant differences in initial latency between experimental groups. Alloxan-induced diabetes significantly decreased retention period latency. #P < 0.05 vs. vehicle control. Atorvastatin significantly attenuated the alloxan-induced diabetes decrease in retention period latency. *P < 0.05 vs. alloxan-induced diabetes; +P < 0.05 vs. alloxan-induced diabetes + liraglutide. Liraglutide also significantly attenuated the alloxan-induced diabetes decrease in retention period latency even more than atorvastatin. ***P < 0.001. Symbols represent each data point and the bar indicates mean ± standard deviation. Statistical analyses were performed using a Kruskal–Wallis test. Ator, atorvastatin; Control, saline vehicle treatment alone as a negative control; DM, alloxan-induced model of diabetes mellitus.
Figure 3
The amount of time spent in the dark compartment by mice in each experimental group. Alloxan-induced diabetes significantly increased the time spent in the dark compartment. #P < 0.05 vs. saline vehicle control. Atorvastatin attenuated this increase in mice with alloxan-induced diabetes. *P < 0.05 vs. alloxan-induced diabetes; +P < 0.05 vs. alloxan-induced diabetes + liraglutide. Liraglutide significantly attenuated the time mice with alloxan-induced diabetes spent in the dark compartment. ***P < 0.001 vs. alloxan-induced diabetes. Symbols represent each data point and the bars indicate mean ± standard deviation. Statistical analyses were performed using a one-way ANOVA with a Tukey post hoc test. ANOVA, analysis of variance; Ator, atorvastatin; Control, saline vehicle treatment alone as a negative control; DM, alloxan-induced model of diabetes mellitus.
Vorschau